NORTH CHICAGO, Ill., Dec. 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced efficacy and safety findings from a Phase 2 study demonstrating that nearly half (48%) of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) had a complete or partial response with single-agent ibrutinib (IMBRUVICA®), as assessed by Independent Review Committee (IRC) investigators. The median duration of response was not reached.1 These data will be presented today in an oral presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA (abstract #1213). IMBRUVICA, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

Oncology researcher Dr. Gary Gordon feels optimistic about the future of cancer treatment. Here’s why.

NORTH CHICAGO, Ill. and BALTIMORE, Dec. 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and the Johns Hopkins University School of Medicine today announced that they signed a five-year collaboration agreement with the goal of advancing medical oncology research and discovery at both organizations.

NORTH CHICAGO, Ill. and CHICAGO, Dec. 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Northwestern University today announced they signed a five-year collaboration agreement with the goal of advancing research and discovery in oncology. Together, AbbVie and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University will work in several areas of oncology research, which in addition to others could include, lung, colorectal, breast, prostate and hematological cancer.

NORTH CHICAGO, Ill., Dec. 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced encouraging efficacy and safety findings from two separate studies evaluating ibrutinib (IMBRUVICA®) as a combination therapy in two of the most common types of non-Hodgkin's lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). IMBRUVICA, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

NORTH CHICAGO, Ill., Dec. 3, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced long-term follow-up results evaluating up to five years of IMBRUVICA® (ibrutinib) use in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In this analysis, 89% of treatment-naïve (TN) and relapsed/refractory (R/R) patients with CLL/SLL, including those with high-risk disease, show a complete or partial response. Further, almost one-third of patients (29%) who received ibrutinib as their first treatment for the disease achieved a complete response (CR), and patients lived without disease progression longer when treatment was started earlier in the course of the disease (abstract #233). 

Learn more about the symptoms and treatment of chronic lymphocytic leukemia (CLL).

NORTH CHICAGO, Ill., Nov. 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, being investigated in combination with chemotherapies, such as carboplatin and paclitaxel, or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).

NORTH CHICAGO, Ill., Nov. 3, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data from 25 abstracts evaluating an important variety of investigational uses of the company's portfolio of blood cancer medicines will be presented during the 58th American Society of Hematology (ASH) Annual Meeting, December 3-6, in San Diego, CA.

- CHMP recommends VENCLYXTO monotherapy for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor